RecruitingPhase 1NCT06465316

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma

Sponsor

National Cancer Institute (NCI)

Enrollment

26 participants

Start Date

Dec 6, 2024

Study Type

INTERVENTIONAL

Conditions

Refractory Multiple Myeloma Recurrent Multiple Myeloma

Summary

This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing the combination of two drugs — teclistamab (a bispecific antibody) and iberdomide (an immunomodulatory drug) — for multiple myeloma (a blood cancer) that has relapsed or stopped responding to multiple prior treatments. **You may be eligible if...** - You have confirmed multiple myeloma that has progressed after at least 4 prior treatment regimens - Your prior treatments must have included a proteasome inhibitor (e.g., bortezomib), an immunomodulatory drug (e.g., lenalidomide), and an anti-CD38 antibody (e.g., daratumumab) - If you had a stem cell transplant, at least 100 days must have passed **You may NOT be eligible if...** - You have had fewer than 4 prior lines of therapy - You have significant organ dysfunction or active infections Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo blood and urine sample collection

PROCEDUREBone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDUREBone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDUREComputed Tomography

Undergo PET/CT

DRUGIberdomide

Given PO

PROCEDUREMagnetic Resonance Imaging

Undergo PET/MR

PROCEDUREPositron Emission Tomography

Undergo PET/CT or PET/MR

DRUGTeclistamab

Given SC

Locations(14)

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, United States

Smilow Cancer Hospital-Derby Care Center

Derby, Connecticut, United States

Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, United States

Yale University

New Haven, Connecticut, United States

Yale-New Haven Hospital North Haven Medical Center

North Haven, Connecticut, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

University of Kansas Cancer Center

Kansas City, Kansas, United States

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, United States

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06465316

Related Trials

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

NCT064216755 locations

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT066220051 location

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT0643394711 locations

Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

NCT070457271 location

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT0623204440 locations